Related Experiment Video
Updated: Jun 27, 2025
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in
Ruth Moulson1, Jennifer Law2, Adrian Sacher2
1Pentavere, 460 College Street, Toronto, ON M6G 1A1, Canada.
Current Oncology (Toronto, Ont.)
|April 26, 2024
Summary
Real-world data shows limited survival post-osimertinib for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in Canada. Patients with exon 20 insertions (ex20ins) had better outcomes, indicating a need for novel therapies.
Area of Science:
- Oncology
- Genomics
- Real-world evidence
Background:
- Limited real-world data exists for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in Canada.
- Electronic health records (EHRs) offer a valuable source for understanding treatment patterns and outcomes in NSCLC.
- Artificial intelligence (AI) can efficiently extract and analyze complex EHR data.
Purpose of the Study:
- To describe the prevalence of EGFR mutations in advanced NSCLC patients in Canada.
- To analyze treatment patterns and patient outcomes using AI-extracted EHR data.
- To evaluate survival rates associated with specific EGFR mutations and treatments.
Main Methods:
- Utilized DARWEN AI to extract data from EHRs of advanced non-squamous NSCLC patients at University Health Network (UHN).
- Identified patients with common sensitizing EGFR mutations (cEGFRm), exon 20 insertions (ex20ins), and EGFR wild-type.
- Calculated one-year overall survival (OS) rates and analyzed first- and second-line treatment patterns, including osimertinib use.
Main Results:
- Of 613 advanced NSCLC patients, 22% had cEGFRm, 1% had ex20ins, and 55% were EGFR wild-type.
- One-year OS was 88% for cEGFRm, 100% for ex20ins, and 59% for wild-type.
- Survival post-osimertinib was poor (35% post-first-line, 20% post-second-line) for cEGFRm patients; ex20ins patients showed improved outcomes with targeted therapy.
Conclusions:
- Real-world data indicates poor survival outcomes after osimertinib discontinuation in advanced EGFR-mutated NSCLC patients with cEGFR mutations.
- Patients with EGFR exon 20 insertions demonstrated improved outcomes, potentially due to targeted therapies.
- There is a critical need for more effective treatment strategies for advanced EGFR-mutated NSCLC, particularly for cEGFRm and ex20ins subtypes.
